SCHEMBL3205869

SCHEMBL3205869

CC(C)c1nn2ccccc2c1C=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.56
PDE5A O76074 6/20 0.56
PDE3A Q14432 4/20 0.56
ALDH1A1 P00352 4/20 0.56
CYP1A2 P05177 3/20 0.56
CYP2C9 P11712 3/20 0.56
MIF P14174 2/20 0.56
MEN1 O00255 2/20 0.56
CYP3A4 P08684 2/20 0.56
CYP2D6 P10635 2/20 0.56
CYP2C19 P33261 2/20 0.56
KMT2A Q03164 2/20 0.56
TSHR P16473 1/20 0.56
PDE4A P27815 1/20 0.56
ADORA2A P29274 1/20 0.56
ADORA1 P30542 1/20 0.56
BLM P54132 1/20 0.56
PDE4C Q08493 1/20 0.56
PDE4D Q08499 1/20 0.56
PDE3B Q13370 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10809812 0.83 PDE4B (0.51) PDE4BPDE5APDE3AALDH1A1CYP1A2
SCHEMBL10809810 0.83 PDE4B (0.51) PDE4BPDE5APDE3AALDH1A1CYP1A2
SCHEMBL3196384 0.81 PDE4B (0.54) PDE4BPDE5APDE3AALDH1A1CYP1A2
SCHEMBL3070035 0.78 HPGD (0.46) PDE4BPDE5APDE3AALDH1A1CYP1A2
SCHEMBL3197550 0.78 PDE4B (0.53) PDE4BPDE5APDE3AALDH1A1CYP1A2
SCHEMBL3205161 0.78 PDE4B (0.53) PDE4BPDE5APDE3AALDH1A1CYP1A2
SCHEMBL3193018 0.78 PDE4B (0.53) PDE4BPDE5APDE3AALDH1A1CYP1A2
SCHEMBL4522859 0.77 PDE4B (0.52) PDE4BPDE5APDE3AALDH1A1CYP1A2
SCHEMBL9052268 0.77 PDE4B (0.52) PDE4BPDE5APDE3AALDH1A1CYP1A2
SCHEMBL3819361 0.77 MAPK14 (0.44) PDE4BPDE5APDE3AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 US disclosed
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 US disclosed
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 US disclosed
EP-2038279-A2 SUBSTITUTED PYRAZOLO [1,5- ALPHA] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE Avigen, Inc. (US) 2009-03-25 EP disclosed
WO-2007146087-A2 SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2007-12-21 WO disclosed
EP-0368343-B1 AMELIORATING COMPOSITION FOR DYSMNESIA KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1993-06-30 EP disclosed
EP-0270926-B1 AGENTS PROMOTING THE ACTIVITY OF SOME ANTITUMOR AGENTS AND METHODS FOR THEIR PRODUCTION KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1993-03-17 EP disclosed
EP-0368343-A2 Ameliorating composition for dysmnesia KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1990-05-16 EP disclosed
US-4923871-A ANTITUMOR KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1990-05-08 US disclosed
EP-0270926-A2 Agents promoting the activity of some antitumor agents and methods for their production KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1988-06-15 EP disclosed
EP-0118916-B1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM KYORIN PHARMACEUTICAL CO., LTD. (JP) 1987-08-12 EP disclosed
US-4578392-A SRS-A ANTAGONISTS KYORIN PHARMACEUTICAL CO., LTD. (JP) 1986-03-25 US disclosed
EP-0118916-A2 Pyrazolo(1,5-a)pyridine derivatives, process for their preparation and compositions containing them KYORIN PHARMACEUTICAL CO., LTD. (JP) 1984-09-19 EP disclosed
US-4028370-A SMOOTH MUSCLE RELAXANTS, CEREBRAL AND CORONARY DILATORS, HYPOTENSIVE AGENTS KYORIN PHARMACEUTICAL CO., LTD. (JA) 1977-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 PDE4B 383/4885PDE5A 418/4885PDE3A 620/4885
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 PDE4B 383/4885PDE5A 418/4885PDE3A 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.